_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Subscribe To Our Newsletter & Stay Updated
